Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The facility will be positioned as a Centre of Excellence for tertiary care services
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Subscribe To Our Newsletter & Stay Updated
